Source: Health Products Regulatory Authority (IE) Revision Year: 2020 Publisher: Teofarma S.R.L., Valle Salimbene (PV), Via F. LLI Cervi, 8 CAP 27010, Italy
Dosulepin is a tricyclic antidepressant which acts by inhibiting the re-uptake of monoamine neurotransmitters into presynaptic neurone at central nervous system, so producing a clinical antidepressant effect.
Dosulepin, in common with other tricyclics, inhibits the reuptake of noradrenaline and 5-hydroxytryptamine, with a significantly greater action on the uptake of noradrenaline. In addition, dosulepin inhibits the neuronal uptake of dopamine.
As a consequence of its effects on monoamine levels, dosulepin appears to produce adaptive changes in the brain
Similarly to other tricyclic antidepressants, it has anticholinergic, antihistaminic and anti-α1 adrenergic effects.
Dosulepin is readily absorbed from the gastrointestinal tract and extensively metabolised in the liver. Metabolites include northiaden, dosulepin-S-oxide and northiaden-S-oxide. Dosulepin is excreted in the urine, mainly in the form of metabolites; appreciable amounts are also excreted in the faeces. A half-life of about 50 hours has been reported for dosulepin and its metabolites.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
